Stephen K. Tahir

12.4k citations

35 papers · 3.3k indexed · 1 hit paper · h-index 22

Oncology top 5%
- Cancer-related Molecular Pathways 5
Molecular Biology top 5%
- Cell death mechanisms and regulation 13
- Cancer therapeutics and mechanisms 4
Genetics top 5%
- Chronic Lymphocytic Leukemia Research 6
Hematology top 5%
- Multiple Myeloma Research and Treatments 4
Toxicology top 5%
Cell Biology
- Microtubule and mitosis dynamics 5
Immunology
- Phagocytosis and Immune Regulation 4
Cellular and Molecular Neuroscience
- Neuroscience and Neuropharmacology Research 3

Co-authors: Saul H. Rosenberg Christin Tse Haichao Zhang Stephen W. Fesik Xiufen Yang Mark G. Anderson Steven W. Elmore Sha Jin
Cited by: Oncology Molecular Biology Genetics
Journals: Journal of Biological Chemistry (1 paper)Blood (5 papers)Cancer Research (4 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Stephen K. Tahir

33 papers receiving 3.2k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Stephen K. Tahir

Since Specialization

Citations

This map shows the geographic impact of Stephen K. Tahir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen K. Tahir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen K. Tahir more than expected).

Fields of papers citing papers by Stephen K. Tahir

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen K. Tahir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen K. Tahir. The network helps show where Stephen K. Tahir may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Stephen K. Tahir, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Stephen K. Tahir Line = papers co-authored together Stephen K. Tahir links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Targeting tumor intrinsic TAK1 engages TNF-α-driven cell death through distinct mechanisms and enhances cancer immunotherapy Cell Death and Disease ·Jason D. Huska,Kelly Doyle,Julie J. Purkal,Cara L. Hrusch,Ryan Duggan,Erwin R. Boghaert,Andrew J. Souers,Darren C. Phillips,Stephen K. Tahir	2025	0
2	Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia Blood ·Stephen K. Tahir,Emiliano Calvo,Benedito A. Carneiro,Junichiro Yuda,Aditya Shreenivas,Mojca Jongen‐Lavrencic,Eelke Gort,Kenichi Ishizawa,Daniel Morillo,Carla Biesdorf,Morey L. Smith,Cheng Dong,Monica Motwani,David Sharon,Tamar Uziel,Dimple Modi,Fritz G. Buchanan,Susan E. Morgan-Lappe,Bruno C. Medeiros,Darren C. Phillips	2023	9
3	Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors Cancer Research ·Darren C. Phillips,Fritz G. Buchanan,Dong Cheng,Larry R. Solomon,Xiao Yu,John Xue,Stephen K. Tahir,Morey L. Smith,Haichao Zhang,D. L. Widomski,Vivek C. Abraham,Nan Xu,Zhihong Liu,Li Zhou,Enrico L. DiGiammarino,Xin Lü,Nandini Rudra-Ganguly,Bruce A. Trela,Susan E. Morgan-Lappe	2021	32
4	Quantification of BCL-2 Family Members by Flow Cytometry Methods in molecular biology ·Morey L. Smith,Stephen K. Tahir	2018	1
5	Vulnerability of Small-Cell Lung Cancer to Apoptosis Induced by the Combination of BET Bromodomain Proteins and BCL2 Inhibitors Molecular Cancer Therapeutics ·Lloyd T. Lam,Xiaoyu Lin,Emily J. Faivre,Ziping Yang,Xiaoli Huang,Denise M. Wilcox,Richard J. Bellin,Sha Jin,Stephen K. Tahir,Michael J. Mitten,Terry Magoc,Anahita Bhathena,Warren M. Kati,Daniel H. Albert,Yu Shen,Tamar Uziel	2017	55
6	Abbv-621 Is a Novel and Potent TRAIL Receptor Agonist Fusion Protein That Induces Apoptosis Alone and in Combination with Navitoclax and Venetoclax in Hematological Tumors Blood ·Stephen K. Tahir,Morey L. Smith,Larry R. Solomon,Haichao Zhang,John Xue,Xiao Yu,Dong Cheng,Greg Buchanan,Susan E. Morgan-Lappe,Darren C. Phillips	2017	8
7	Potential mechanisms of resistance to venetoclax and strategies to circumvent it BMC Cancer ·Stephen K. Tahir,Morey L. Smith,Paul Hessler,Lisa Roberts Rapp,Kenneth B. Idler,Chang H. Park,Joel Johansson,Lloyd T. Lam	2017	142
8	Genomic analysis and selective small molecule inhibition identifies BCL-XL as a critical survival factor in a subset of colorectal cancer Molecular Cancer ·Haichao Zhang,John Xue,Paul Hessler,Stephen K. Tahir,Jun Chen,Sha Jin,Andrew J. Souers,Joel Johansson,Lloyd T. Lam	2015	43
9	The Bcl-2/Bcl-XL/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo Molecular Cancer Therapeutics ·Jun Chen,Sha Jin,Vivek Abraham,Xiaoli Huang,Bernard A. Liu,Michael J. Mitten,Paul Nimmer,Xiaoyu Lin,Morey L. Smith,Yu Shen,Alexander R. Shoemaker,Stephen K. Tahir,Haichao Zhang,Scott Ackler,Saul H. Rosenberg,Heather Maecker,Deepak Sampath,Joel Johansson,Chris Tse,Steven W. Elmore	2011	119
10	Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines Molecular Cancer Therapeutics ·Stephen K. Tahir,John Wass,Mary K. Joseph,Viswanath Devanarayan,Paul Hessler,Haichao Zhang,Steve W. Elmore,Paul E. Kroeger,Christin Tse,Saul H. Rosenberg,Mark G. Anderson	2010	59
11	The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo Cancer Chemotherapy and Pharmacology ·Scott Ackler,Michael J. Mitten,Kelly Foster,Anatol Oleksijew,Marion Refici,Stephen K. Tahir,Xiao Yu,Christin Tse,David J. Frost,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore,Alexander R. Shoemaker	2010	100
12	ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitorbreakdown → Cancer Research ·Christin Tse,Alexander R. Shoemaker,Jessica Adickes,Mark G. Anderson,Jun Chen,Sha Jin,Eric F. Johnson,Kennan C. Marsh,Michael J. Mitten,Paul Nimmer,Lisa Roberts,Stephen K. Tahir,Xiao Yu,Xiufen Yang,Haichao Zhang,Stephen W. Fesik,Saul H. Rosenberg,Steven W. Elmore	2008	1513
13	Influence of Bcl-2 Family Members on the Cellular Response of Small-Cell Lung Cancer Cell Lines to ABT-737 Cancer Research ·Stephen K. Tahir,Xiufen Yang,Mark G. Anderson,Susan E. Morgan-Lappe,Aparna V. Sarthy,Jun Chen,Robert B. Warner,Shi‐Chung Ng,Stephen W. Fesik,Steve W. Elmore,Saul H. Rosenberg,Christin Tse	2007	250
14	Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains Molecular Cancer Research ·Edward T. Olejniczak,Charles Van Sant,Mark G. Anderson,Gang Greg Wang,Stephen K. Tahir,Guido Sauter,Rick Lesniewski,Dimitri Semizarov	2007	53
15	Survivin Enhances Aurora-B Kinase Activity and Localizes Aurora-B in Human Cells Journal of Biological Chemistry ·Jun Chen,Sha Jin,Stephen K. Tahir,Haichao Zhang,Xuesong Liu,Aparna V. Sarthy,Thomas McGonigal,Zhihong Liu,Saul H. Rosenberg,Shi‐Chung Ng	2002	101
16	Abrogation of G2 checkpoint specifically sensitize p53 defective cells to cancer chemotherapeutic agents. PubMed ·Yan Luo,Shayna K. Rockow-Magnone,Mary K. Joseph,Jay Bradner,Christopher Butler,Stephen K. Tahir,Edward K. Han,Shi‐Chung Ng,Jean M. Severin,Earl J. Gubbins,Regina M. Reilly,Annemarie Rueter,Robert L. Simmer,Tom Holzman,Vincent L. Giranda	2001	28
17	Down-regulation of Survivin by Antisense Oligonucleotides Increases Apoptosis, Inhibits Cytokinesis and Anchorage-Independent Growth Neoplasia ·Jun Chen,Wei Wu,Stephen K. Tahir,Paul E. Kroeger,Saul H. Rosenberg,Lex M. Cowsert,Frank Bennett,Stanisław Krajewski,Maryla Krajewska,Kate Welsh,John C. Reed,Shi‐Chung Ng	2000	169
18	Potent inhibitors of protein farnesyltransferase: Heteroarenes as cysteine replacements Bioorganic & Medicinal Chemistry Letters ·Shen Wang,Stephen A. Fakhoury,Greg Donner,Kenneth J. Henry,Jang Lee,Haichao Zhang,Jerry D. Cohen,Robert R. Warner,Badr Saeed,Sajeev Cherian,Stephen K. Tahir,Peter Kovar,Joy Bauch,Shi‐Chung Ng,Kennan Marsh,Hing L. Sham,Saul H. Rosenberg	1999	7
19	CANNABINOID ENANTIOMER ACTION ON THE CYTOARCHITECTURE Cell Biology International ·Ronald G. Wilson,Stephen K. Tahir,Raphael Mechoulam,Selma Zimmerman,Arthur M. Zimmerman	1996	25
20	Cytoskeletal organization following cannabinoid treatment in undifferentiated and differentiated PC12 cells Biochemistry and Cell Biology ·Stephen K. Tahir,Judy Trogadis,John K. Stevens,Arthur M. Zimmerman	1992	54

About Stephen K. Tahir

Stephen K. Tahir is a scholar working on Hematology, Genetics and Oncology, having authored 35 papers that have together received 3.3k indexed citations. Recurring topics across this work include Cell death mechanisms and regulation (13 papers), Chronic Lymphocytic Leukemia Research (6 papers), Microtubule and mitosis dynamics (5 papers), Cancer-related Molecular Pathways (5 papers), Multiple Myeloma Research and Treatments (4 papers), Cancer therapeutics and mechanisms (4 papers), Phagocytosis and Immune Regulation (4 papers) and Neuroscience and Neuropharmacology Research (3 papers). The work is most often cited by research in Oncology (980 citations), Molecular Biology (2.4k citations) and Genetics (344 citations). Stephen K. Tahir has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Saul H. Rosenberg, Christin Tse, Haichao Zhang, Stephen W. Fesik, Xiufen Yang, Mark G. Anderson, Steven W. Elmore, Sha Jin, Alexander R. Shoemaker and Paul Nimmer. Their work appears in journals such as Journal of Biological Chemistry, Blood and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact